Abstract
CSL112 (Apolipoprotein A-I [human]
) is a novel formulation of intravenous plasma-derived apolipoprotein A-I (apoA-I) formulated with phosphatidylcholine (PC) and stabilized with sucrose. CSL112 is being developed to enhance cholesterol efflux from coronary plaque to reduce the risk of recurrent cardiovascular events in the first weeks and months following an acute myocardial infarction (AMI), 1 when the risk of experiencing such events is high. [2] [3] [4] Importantly, reduced renal function is known to increase the risk of having a recurrent AMI, and patients with moderate/severe renal impairment (RI) (estimated glomerular filtration rate [eGFR] <40 mL/min/1.73 m 2 ) have been shown to have a significantly higher rate of reinfarction (approximately 3-fold) than those with an eGFR ࣙ 75.0 mL/min/1.73 m. 5 The pharmacokinetics (PK), safety, and tolerability of CSL112 in healthy subjects were previously reported in single-and multiple-ascending dose studies. 6 In the multiple-ascending dose study, 36 healthy subjects with normal renal function were randomized to receive CSL112 once weekly (3.4 or 6.8 g) or twice weekly (3.4 g). 6 Peak plasma concentrations of apoA-I were observed by the end of the 2-hour infusion, followed by a biphasic decline and a dose-dependent increase in C max . No accumulation of apoA-I or PC was observed with weekly dosing. The PK profile of PC, a formulation component of CSL112, which is used to reconstitute apoA-I into disc-shaped particles suitable for intravenous infusion, showed a pattern similar to that of apoA-I, with C max reached by the end of the 2-hour infusion. Again, similar to apoA-I, this was followed by a biphasic decline, albeit with a shorter half-life than apoA-I. The volume of distribution of CSL112 was found to be slightly higher than total plasma volume, indicating that CSL112 undergoes a degree of distribution into extravascular fluids and tissues. To date, the PK of sucrose following CSL112 administration has not been studied; however, it is known that sucrose undergoes significant renal excretion. 7 In a phase 2a single-ascending dose study, the PK and safety of CSL112 were investigated in subjects with mild RI (eGFR ࣙ 60 to < 90 mL/min/1.73 m 2 ) and stable atherosclerotic disease. 8 Similar to results observed in the phase 1 study, rapid dose-dependent increases in serum apoA-I (up to 244% of baseline levels with the 6.8 g dose) were noted, with no signs of drug-related renal toxicity detected. Furthermore, a recent phase 2b study of 4 weekly doses of CSL112 in subjects with AMI included 419 patients with mild RI. For both the low (2 g) and high (6 g) doses, PK profiles were similar in subjects with normal renal function and mild RI. 9 In addition, both doses were well tolerated, with no significant renal safety changes compared with placebo. 10 These findings established that there is no need for dose adjustment in AMI patients with mild RI.
RI is known to be a common comorbidity in cardiovascular disease; therefore, AMI patients with RI will likely constitute a significant proportion of the patient population that may benefit from CSL112. Consequently, preliminary PK and safety profile data for CSL112 in patients with moderate RI are required prior to their inclusion in further clinical studies of CSL112 to determine whether dose adjustment is required in this population. Here we report the findings of a phase 1 PK and safety study in subjects with moderate RI (eGFR ࣙ 30 and <60 mL/min/1.73 m 2 ) compared with age-, weight-, and sex-matched subjects with normal renal function (eGFR ࣙ 90 mL/min/1.73 m 2 ).
Methods
This study (NCT02427035) was conducted at 4 centers in the 
Study Design
This was a phase 1, double-blind, placebo-controlled single-ascending dose study, with a 1:1 ratio between subjects with moderate RI and subjects with normal renal function matched for sex, age, and weight. Subjects were randomized 3:1 within a renal function cohort to receive a single 2-hour intravenous infusion of CSL112 (2 or 6 g) or placebo. The cohort receiving 2 g CSL112 and matched placebo was dosed first; dosing in the 6 g cohort was commenced after review of 2 g data by the Data and Safety Monitoring Board ( Figure 1A ). The study consisted of a 28-day screening period, a 16-day active treatment period that included a mandatory in-house study unit stay, several outpatient visits, and a 76-day safety follow-up period ( Figure 1B) .
The primary end points were the plasma PK parameters for apoA-I and PC, and the urinary excretion profile of apoA-I. Secondary end points included the plasma PK and urinary excretion profile of sucrose and the safety and tolerability of CSL112.
CSL112
CSL112 is an investigational product containing apoA-I purified from human plasma and formulated with PC, with sucrose as a stabilizing agent.
1 CSL112 was administered as a dose of 2 or 6 g. Subjects randomized to receive placebo were given a volume of 0.9% saline matched for each dose of CSL112.
Study Population
Adults with moderate RI, as defined by an eGFR ࣙ 30 and <60 mL/min/1.73 m 2 , and sex-, age-, and weight-matched subjects with normal renal function (eGFR ࣙ 90 mL/min/1.73 m 2 ) were enrolled; eGFR was determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
11
The study included male and female subjects aged 18 to 85 years with a body weight of at least 50 kg at screening. Details of the subject-matching process between renal function cohorts can be found in Supplementary  Table 1 . Key exclusion criteria were evidence of an unstable or uncontrolled medical condition, disorder, or disease; evidence of hepatobiliary disease; evidence of hemodynamic instability by heart rate or blood pressure criteria; known history of hypersensitivity to soy or peanuts or an IgA deficiency; other severe comorbid condition; concurrent medication or other issue that renders the subject unsuitable for participation in the study (eg, acute renal failure, history of organ transplant, cancer, thrombocytopenia or coagulopathy, HIV infection, pregnancy, and alcohol or substance abuse), and current participation in another clinical trial.
Pharmacokinetics of Apoa-I, PC, and Sucrose
Blood samples were collected 2 days prior and immediately before dosing and 2, 4, 6, 8, 12, 24, 48, 72, 96, and 144 hours after infusion. Urine sample collection took place over the following time intervals: 24-20, 20-16, 16-12, and 12-0 hours prior to infusion and 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours postinfusion. ApoA-I was measured in plasma and urine using immunoturbidometric (Roche/Hitachi Modular P automated clinical chemistry analyzer and K-Assay Apo AI assay; Kamiya Biomedical Company, Tukwila, Washington) and enzyme-linked immunosorbent assays (Molecular Devices VersaMaz plate reader and AssayMax Apolipoprotein A-I ELISA kit; AssayPro, St. Charles, Missouri), respectively. PC was quantified enzymatically in plasma using phospholipase and choline oxidase forming hydrogen peroxide (Wako Phospholipids C assay; Wako Pure Chemical Industries, Osaka, Japan); the resultant blue pigment was measured spectrophotometrically at a primary wavelength of 600 nm and a secondary wavelength of 700 nm (Roche/Hitachi Modular P automated clinical chemistry analyzer; Kamiya Biomedical Company, Tukwila, Washington). Sucrose was measured in plasma and urine using a 2-step reaction whereby invertase (Invertase from baker's yeast; Fluka, distributed by Sigma Aldrich, St. Louis, Missouri) converted sucrose into fructose and glucose, which was then measured using a hexokinase automated chemistry assay (Roche/Hitachi Modular P automated clinical chemistry analyzer; Kamiya Biomedical Company, Tukwila, Washington).
The following plasma PK parameters for apoA-I, PC, and sucrose were calculated by noncompartmental PK analysis on unadjusted and baseline-corrected data using Phoenix WinNonlin, version 6.3: AUC 0-inf , area under the plasma concentration-time curve from baseline extrapolated to infinity; AUC 0-last , area under the plasma concentration-time curve from baseline to the last quantifiable point before analyte first returns to baseline; C max , observed maximum plasma concentration; T max , time to reach C max ; Vz, volume of distribution during terminal phase after intravenous administration; CL, systemic plasma clearance; and 
Safety
Safety end points were: the occurrence of any adverse event (AE) after the start of the infusion, renal and hepatic safety and tolerability, clinically significant changes in laboratory tests, physical examinations, body weight, vital signs, and immunogenicity.
Statistical Analysis
The study was exploratory and not designed to evaluate formal hypotheses. Sample sizes were deemed sufficient to assess PK and safety. Descriptive analysis of concentration data was performed for plasma apoA-I, PC, and sucrose.
Results

Study Population
A total of 76 subjects provided written consent and were screened for inclusion in the study. Of these, 32 subjects were enrolled, 16 subjects with moderate RI and 16 subjects with normal renal function. Subjects were randomly assigned within renal function groups to receive CSL112 2 g (n = 12), CSL112 6 g (n = 12), or placebo (n = 8). Safety and tolerability were assessed in all 32 subjects and PK parameters in the 24 subjects randomized to receive CSL112. Study population demographics and baseline characteristics are provided in Table 1 . Baseline group mean eGFR values were 100.5 and 49.1 mL/min/1.73 m 2 for the normal renal function and moderate RI groups, respectively. Moderate RI subjects were older than those with normal renal function (mean age, 69 vs 55 years) but were well matched for weight (mean weight, 80.5 vs 78 kg).
Primary End Points: PK Profiles for Apoa-I and PC
Mean apoA-I and PC plasma concentrations were similar between renal function and dose groups at baseline (Table 1) . Following infusion of CSL112, mean (unadjusted and baseline corrected [data not shown]) apoA-I and PC plasma concentration-time profiles were between in renal function groups (Figure 2) . The increase in apoA-I was dose dependent and peaked at the end of the infusion, with a T max of approximately 2 hours for all dose levels and renal function groups. In addition, there were dose-dependent increases in C max , AUC 0-72 , and AUC 0-last for both apoA-I and PC, irrespective of renal function (Table 2 ). Based on comparison of geometric least-square means of C max and AUC at each dose level, there were no significant differences in plasma exposure to CSL112 (ie, apoA-I and PC) between renal function groups.
Linear regression analysis showed that plasma clearance of apoA-I was largely unaffected by lower eGFR in subjects with moderate RI (Figure 3) . At the CSL112 6 g dose level, it was possible to calculate mean ± standard deviation t 1/2 for baseline-corrected apoA-I for Figure 2 . Plasma pharmacokinetic profiles of apolipoprotein A-I and phosphatidylcholine following CSL112 infusion. Shown are mean + standard deviation unadjusted (A) apolipoprotein A-I (apoA-I) and (B) phosphatidylcholine (PC) plasma concentration-time profiles by renal function group, moderate renal impairment (RI), and normal renal function following infusion of CSL112 2 or 6 g. Please note that the small differences in the 2 g curves are attributable to differences in values at baseline rather than differences in response to CSL112. Values are the arithmetic mean ± standard deviation or median (range). AUC, area under the curve; 0-last, time zero to the last quantifiable point (following baseline correction); C max , maximum concentration in plasma; ND, not determined; RI, renal impairment; T max , time to maximal plasma concentration; t 1/2 , terminal half-life subjects with moderate RI and for those matched subjects with normal renal function (91.8 ± 28.0 and 97.8 ± 59.3 hours, respectively). The fraction of apoA-I excreted in the urine 48 hours after infusion of CSL112 was <1% across all dose and renal function cohorts.
PK Profile of Sucrose
At baseline, plasma sucrose levels were below the limit of quantification or negligible in all groups (Table 1) . Mean unadjusted C max values for sucrose were similar for both renal function groups at each dose level (Table 2 ). However, mean unadjusted plasma sucrose concentration-time profiles in subjects with moderate RI showed slower elimination when compared with subjects with normal renal function at both doses (Figure 4 ). Despite this, levels returned to baseline after 24 hours regardless of renal function (Figure 4 ).
There was a dose-dependent increase in the amount of sucrose in urine in both renal function cohorts. In the first 12 hours after administration of CSL112, 55%-70% of the infused sucrose was excreted, with 30%-40% excreted within the first 4 hours (Table 3 ). At the 6 g CSL112 dose, the time course for excretion of sucrose was slower in subjects with moderate RI; however, after 48 hours of urine collection, the total amount excreted by each group was similar. (Table 4) . Overall, fewer subjects with moderate RI than with normal renal function had at least 1 AE: n = 4 versus n = 10, respectively. Rates of AEs were highest at the CSL112 6 g dose for both subjects with moderate RI (3 of 6 subjects [50.0%]) and subjects with normal renal function (5 of 6 subjects [83.3%]). No subjects had serious treatment-related AEs. No deaths occurred during the study, and no subjects discontinued from the study because of an AE.
Safety Adverse Events. Fourteen of 32 subjects (2 of 8 placebo [25%] and 12 of 24 CSL112 [50%]) experienced AEs
A total of 7 subjects (4 with moderate RI and 3 with normal renal function) had treatment-related AEs, which were considered mild or moderate in severity. The most frequently reported AEs, which were more common in subjects dosed with CSL112, were headache, in 2 of 6 patients with normal renal function receiv- ing CSL112 6 g (33.3%), and increased blood bilirubin (<1.5 × the upper limit of normal [ULN] and resolved within 24 hours) in 2 of 6 patients with moderate RI receiving CSL112 6 g (33.3%). There were no subjects with clinically significant elevations in liver transaminases and no subjects with concomitant elevations in total bilirubin and liver transaminases.
Renal and Hepatic Safety. Overall, no clinically meaningful renal safety changes were observed in any of the dose/renal function groups. In all subjects, there were no clinically significant increases in serum creatinine levels, that is, a ࣙ1.5-fold increase from baseline values during the treatment period. In addition, there were no clinically significant changes in eGFR.
At baseline, cystatin C values were higher in subjects with moderate RI compared with normal renal function subjects. Following infusion of CSL112, shifts in cystatin C above the ULN occurred in 3 subjects with moderate RI (2 subjects in the 2 g CSL112 dose group Values are the arithmetic mean ± standard deviation. and 1 subject in 6 g CSL112 dose group). Furthermore, over 24 hours, absolute mean changes in cystatin C were similar between renal function groups. There were also transient dose-dependent increases in urinary cystatin C/creatinine ratios following infusion of CSL112 in all renal function groups, with maximal ratios observed at the 0-to 4-hour interval (Supplementary Table 2) ; however, this was not related to changes in eGFR (Supplementary Figure 1) . Urine KIM-1/creatinine ratios were higher in the group of patients with moderate RI receiving CSL112 6 g; however, this was because of 2 individuals with higher baseline values. Ratios were higher across each interval in these individuals but remained stable. Overall, KIM-1/creatinine ratios were similar across renal function and dose groups (Supplementary Table 2) .
Total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase were measured to assess hepatic safety, and no clinically meaningful changes in hepatic function were observed. There were no potential Hy's Law cases (ie, concomitant elevation of ALT/AST and total bilirubin). One subject receiving CSL112 6 g in the normal renal function group had a postbaseline increase in total bilirubin of ˃1.5 to ࣘ2.0 × ULN at study visit 5 (day 2); however, bilirubin levels were within the normal range at study visit 8 (day 5) -this event was not reported as an AE.
Other Safety Measures. No clinically meaningful changes in other clinical laboratory tests, physical examinations, body weight, or vital signs were observed. No subjects developed anti-apoA-I or anti-CSL112 antibodies.
Discussion
The aim of the present investigation was to determine the PK profile, safety, and tolerability of CSL112 in subjects with moderate RI. The primary outcomes of interest were the PK of apoA-I and PC. We found that following a single infusion of CSL112, PK parameters for apoA-I and PC increased in a dose-dependent manner, and there were no significant differences in CSL112 plasma exposure (C max and AUC) between subjects with normal renal function and subjects with moderate RI. As a secondary outcome, the PK profile of sucrose was assessed. As expected, plasma sucrose had a slower elimination in subjects with moderate RI when compared with subjects with normal renal function at both doses. However, despite this, approximately 70% of sucrose was excreted in the 48 hours postinfusion in both renal function groups. In addition, results of the safety analysis showed that CSL112 was well tolerated in both treatment groups; no clinically significant renal function changes were observed, and there were no serious treatment-related AEs.
In this study, infusion of CSL112 resulted in elevations of plasma apoA-I and PC up to the end of the 2-hour infusion, with subsequent biphasic decline, consistent with previous studies. 6, 12 In a phase 2a study, subjects with mild RI and stable atherosclerosis had slightly increased apoA-I and PC exposure compared with subjects with normal renal function. 8 This is believed to be because of the difference in weight observed between renal function groups -body weight was included as a covariate in a previously conducted population PK model of CSL112 and was found to have a significant impact on clearance of apoA-I. 13 After accounting for the differences in weight, renal function was not found to be a significant covariate in the clearance of apoA-I. 13 In contrast, in the present study, groups were well matched by mean weight, and no differences in apoA-I and PC exposure were observed between renal function cohorts.
We observed that <1% of administered apoA-I was excreted in urine as intact apoA-I. However, this finding does not rule out substantial renal filtration and metabolism of apoA-I. 14 The proximal tubules in the kidney express cubilin, a membrane protein that binds apoA-I in the ultrafiltrate and salvages the filtered apoA-I. 15 Animals 15 and humans 16 with a cubilin deficiency show high levels of intact apoA-I in the urine. Our finding of low apoA-I in the urine thus indicates that the ability of the proximal tubule to reabsorb apoA-I via the cubilin pathway is preserved in moderate RI.
A further consideration is the renal handling of sucrose. It is known that sucrose in plasma, in contrast to glucose, is subject to limited tubular reabsorption in the kidney and therefore undergoes significant renal excretion. 7 In line with this, in the present study, it was observed that following CSL112 infusion, the majority of the administered sucrose was rapidly cleared from the blood via glomerular filtration. Therefore, it was not unexpected that sucrose had a longer plasma elimination time in moderate RI subjects compared with subjects with normal renal function. However, importantly, the overall amount of sucrose excreted over 48 hours was similar to that in those with normal renal function and there was no indication of any renal toxicity.
The safety results of this study show that moderate RI did not influence the incidence or severity of AEs, and no clinically significant renal or hepatic function changes were observed. These findings are consistent with those from a previous single-dose study in stable atherosclerotic disease patients with mild RI. 8 The present results also add to the favorable safety profile of CSL112; multiple doses in healthy subjects and in mild RI patients post-AMI have been shown to be safe and well tolerated. 6, 10 In conclusion, moderate RI does not impact the PK or safety profile of CSL112 (Apolipoprotein A-I [human]), and a dose adjustment is not required. Therefore, this study supports the dose selection of CSL112 6 g for further clinical trials in patients who experience an AMI, including those with moderate RI.
